V. B. Rao

This study develops a mucosal nanoparticle flu vaccine using CRISPR-Cas to engineer bacteriophage T4, showing it induces both mucosal and systemic immunity in mice.

The paper investigates how genomic modifications in phage T4 DNA affect its resistance to nuclease-based defense systems in E. coli, revealing roles beyond simple DNA degradation prevention.

This paper develops a bacteriophage-based mucosal vaccine that induces strong immune responses and protects against SARS-CoV-2 and its variants without requiring needles or adjuvants.

The paper shows that CD4-targeted bacteriophage T4 nanoparticles reactivate HIV-1 latency in CD4+ T-cells without global activation or cytokine storm.

The paper identifies a genetic shift in an HIV-1 transmitted/founder virus that leads to broader antibody responses by altering the V2 domain structure.

This study demonstrates a T4 phage-based vaccine platform that incorporates M2e antigens, showing high immunogenicity and complete protection against influenza without adjuvants.

The paper determines the composition of the bacteriophage T4 DNA packaging motor and shows that it can tolerate an inactive subunit, challenging the idea of strict coordination among motor subunits.

This paper develops a CRISPR-engineered bacteriophage T4 nanoparticle platform to create multiplex SARS-CoV-2 vaccine candidates, showing potent immune responses and protection in animal models.